Front. Oncol. Frontiers in Oncology Front. Oncol. 2234-943X Frontiers Media S.A. 10.3389/fonc.2019.00466 Oncology Technology Report OSblca: A Web Server for Investigating Prognostic Biomarkers of Bladder Cancer Patients Zhang Guosen 1 † Wang Qiang 1 † Yang Mengsi 1 Yuan Quan 1 Dang Yifang 1 Sun Xiaoxiao 1 An Yang 1 Dong Huan 1 Xie Longxiang 1 Zhu Wan 2 Wang Yunlong 3 Guo Xiangqian 1 * 1Cell Signal Transduction Laboratory, Department of Preventive Medicine, Bioinformatics Center, School of Basic Medical Sciences, School of Software, Institute of Biomedical Informatics, Henan University, Kaifeng, China 2Department of Anesthesia, Stanford University, Stanford, CA, United States 3Henan Bioengineering Research Center, Zhengzhou, China

Edited by: Prashant Patel, University of Birmingham, United Kingdom

Reviewed by: Piotr Bryniarski, Medical University of Silesia, Poland; Vadim S. Koshkin, University of California, San Francisco, United States

 *Correspondence: Xiangqian Guo xqguo@henu.edu.cn

This article was submitted to Genitourinary Oncology, a section of the journal Frontiers in Oncology

†These authors have contributed equally to this work

 04 06 2019 2019 9 466 05 03 2019 15 05 2019 Copyright © 2019 Zhang, Wang, Yang, Yuan, Dang, Sun, An, Dong, Xie, Zhu, Wang and Guo. 2019 Zhang, Wang, Yang, Yuan, Dang, Sun, An, Dong, Xie, Zhu, Wang and Guo

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

Bladder cancer (BC) is one of the most common malignant tumors in the urinary system. The discovery of prognostic biomarkers is still one of the major challenges to improve clinical treatment of BC patients. In order to assist biologists and clinicians in easily evaluating the prognostic potency of genes in BC patients, we developed a user-friendly Online consensus Survival tool for bladder cancer (OSblca), to analyze the prognostic value of genes. The OSblca includes gene expression profiles of 1,075 BC patients and their respective clinical follow-up information. The clinical follow-up data include overall survival (OS), disease specific survival (DSS), disease free interval (DFI), and progression free interval (PFI). To analyze the prognostic value of a gene, users only need to input the official gene symbol and then click the “Kaplan-Meier plot” button, and Kaplan-Meier curve with the hazard ratio, 95% confidence intervals and log-rank P-value are generated and graphically displayed on the website using default options. For advanced analysis, users could limit their analysis by confounding factors including data source, survival type, TNM stage, histological type, smoking history, gender, lymph invasion, and race, which are set up as optional parameters to meet the specific needs of different researchers. To test the performance of the web server, we have tested and validated its reliability using previously reported prognostic biomarkers, including KPNA2, TP53, and MYC etc., which had their prognostic values validated as reported in OSblca. In conclusion, OSblca is a useful tool to evaluate and discover novel prognostic biomarkers in BC. The web server can be accessed at http://bioinfo.henu.edu.cn/BLCA/BLCAList.jsp.

 bladder cancer prognostic biomarker analysis web server kaplan-meier curve cox regression model No.81602362 National Natural Science Foundation of China10.13039/501100001809 Introduction

As one of the most common malignant tumors of the urinary system, bladder cancer (BC) is estimated to cause about 549,393 new cases and 199,922 deaths worldwide in 2018 (1). Based on the clinic-pathological features, BC could be classified into two types: non-muscle invasive tumor (NMIBC, 70–80% of BC patient) and muscle-invasive tumor (MIBC, 20–30% of BC patient) (2, 3). Due to the relatively high rate of local recurrence and metastasis in MIBC patients, the treatment outcome is still poor, and the survival rate is lower than that of NMIBC patients. Although NMIBC patients have better survival rates than MIBC, 30–50% of NMIBC patients experience cancer recurrence (4). One of the major challenges to improve clinical outcomes of BC patients is to screen novel biomarkers for diagnosis and prognosis (5).

In recent years, a large number of prognostic biomarkers including DNA markers and protein markers have been reported (6–8). Some of the prognostic biomarkers, especially the ones involved in biological processes, are useful to identify high-risk patients, and could be used to predict the prognosis and treatment response. However, few biomarkers have been translated into clinics due to the lack of independent validation (5, 9, 10). With the advance of high through-put technologies, more and more studies analyzed the gene expression of cancer samples and uploaded these data on public databases such as The Cancer Genome Atlas (TCGA, https://portal.gdc.cancer.gov/) and Gene Expression Omnibus (GEO, https://www.ncbi.nlm.nih.gov/geo/). These data offer opportunities for the biomarker discovery, validation, and clinical application (11, 12). Unfortunately, until now, this convenient online tool is still unavailable to clinicians and biologists to evaluate and verify the prognostic value of the genes of interests in different datasets for BC.

To solve this problem, we developed an online web server named OSblca, which consists of gene expression profiles and relative clinical information of 1,075 bladder cancer patients from seven independent cohorts collected from TCGA and GEO databases. This web server enables researchers and clinicians to analyze the prognostic value of a gene of interest and accelerates the development of prognostic biomarkers.

 Methods Datasets Collection

Gene expression profiles and clinical follow-up information of bladder cancer patients were collected from TCGA and GEO databases. For TCGA dataset, level-3 gene expression profiling data (HiSeqV2) and clinical information of BC samples were downloaded in April 2018. In order to collect the relative datasets from GEO, keywords including “bladder cancer,” “prognosis,” “survival,” and “gene expression” were used to search in GEO database. Next, manual checks of the availability of data of mRNA expression, clinical survival information and at least 50 patients were performed.

 Development of OSblca

The OSblca web server was developed by Java script, and hosted by Tomcat 7.0 on Windows 2008. The database system that stores the gene expression and clinical data was handled by SQL Server 2008. The R package “RODBC” is used as a middleware to connect R and SQL. The input of OSblca web server must be the official gene symbol from NCBI (https://www.ncbi.nlm.nih.gov/). The outputs include Kaplan Meier (KM) survival curves, Hazard ratio (HR with 95% confidence interval) and log-rank P-value that are produced by R package “survival” (https://CRAN.R-project.org/package=survival). A gene could be regarded as a potential prognostic biomarker for BC patients when the log-rank P-value is < 0.05. OSblca can be accessed at http://bioinfo.henu.edu.cn/BLCA/BLCAList.jsp. A web server architecture diagram is presented in Figure 1A. The screenshot of the web server interface and the result are shown in Figure 1B.

Diagram of web server architecture (A) and screenshot of OSblca main interface (B).

 Validation of Previously Published Prognostic Biomarkers in OSblca

In order to validate the performance of prognostic analysis in our web server, prognosis biomarkers for BC were searched in PubMed using the keywords “bladder cancer,” “survival,” “gene expression,” “biomarker,” and “prognosis.” The prognostic capabilities of these genes were evaluated in all cohorts, and all cutoff values in “splitting the patients” were tested in each cohort to get the best cutoff value.

 Results Clinical Characteristics of the Patients in OSblca

According to our criteria, in total 1,075 unique bladder cancer patients were collected from seven data sets including one TCGA cohort and six GEO cohorts. Survival information including overall survival (OS), disease specific survival (DSS), disease free interval (DFI), progression free interval (PFI) were gathered. No patient was lost to follow-up. Of the above, 935 patients have overall survival information, and the median overall survival time is 25.03 months. We also collected age, TNM stage, histological type, gender, smoking history, lymph invasion and race as confounding clinical factors. The average age is 68 ± 11. Distribution of TNM stages is as follows: stage I (n = 287, 29.64%), stage II (n = 233, 23.26%), stage III (n = 239, 23.85%), and stage IV (n = 209, 20.86%). The ratio of male to female of patients was close to 3:1. A summary of clinical properties for each dataset is presented in Table 1.

Clinical characteristics of the BC patients collected in OSblca.

Data source Platform Sample size Age No. of death Media (OS) Gender (% male) Stage (%I/II/III/IV/NAa) Never smokers (%) Survival terms
TCGA Illumina HiSeqV2 407 69 ± 11 155 16.93 73.71 0.49/31.70/34.40/32.92/0.49 26.78 OS, DSS, DFI, PFI*
GSE13507 GPL6102 165 65 ± 12 69 36.57 – 48.48/15.76/11.52/10.30/13.94 – OS
GSE19915 GPL3883/GPL5186 140 24 – – 69.29/12.14/15.00/2.14/1.43 – DSS
GSE31684 GPL570 93 69 ± 10 65 31.31 71.12 16.13/18.28/45.16/20.43/0.00 19.35 OS, DSS, DFI, PFI
GSE32548 GPL6947 130 70 ± 11 25 53.77 76.15 70.00/29.23/0.00/0.00/0.77 – OS, DSS, DFI, PFI
GSE48075 GPL6947 73 69 ± 10 45 30.40 – – – OS
GSE48276 GPL14951 67 31 34.10 80.60 2.99/8.96/25.37/53.73/8.95 OS, DSS
Total 1075 68 ± 11 414 25.03 74.46 29.64/23.26/23.85/20.86/3.39 11.81

NA, Not Available;

“–,” no data;

DFI and PFI were defined by (13).

 Survival Analysis of BC Patients Based on Clinical Characteristics

The Kaplan-Meier plots for the bladder cancer patients in OSblca stratified by TNM stage, histological type, gender, smoking history, lymph invasion, and race are presented in Figure 2. In these 1,075 patients, TNM stage, smoking history, lymph invasion, and histological type were significantly associated with overall survival (P < 0.0001, P = 0.0206, P < 0.0001, and P < 0.0001, respectively), which were consistent with previously reports (14–16). Nevertheless, gender and race showed no significant association with overall survival (P = 0.2260 and P = 0.5513).

Survival analysis of clinical characteristics of the bladder cancer patients in OSblca. (A) TNM stage; (B) Lymph invasion; (C) Smoking history; (D) Histological type; (E) Gender; (F) Race.

 Usage of OSblca

The main function that OSblca provides is to evaluate and verify the prognostic value for a given gene. “Gene symbol,” “Data source,” “Survival,” and “Split patients” are set as the four main parameters. The input dialog box of “Gene symbol” is on the upper left of the OSblca page (Figure 3A). A red prompting message will show up when the input is not an official gene symbol. “Data source” provides eight options including independent analysis in one of seven cohorts and in a combined cohort consisting of all the BC patients from seven cohorts. The users can choose to evaluate the prognosis of a given gene in an individual cohort or in a combined cohort according to their needs. Under “Survival” option, four prognostic terms including OS, DSS, DFI, and PFI are provided. In the “Split patients” dialog box, user can select different thresholds of gene expression levels to divide patients into two subgroups for input gene. After then, by clicking the “Kaplan-Meier plot” button, OSblca server will take the request and return the analysis results, which are graphically displayed and presented with HR, 95% CI and log-rank P-value (Figure 3B).

Input and output interface of OSblca. (A) The options of main input parameters and clinical factors of OSblca; (B) The output interface of OSblca.

In order to meet the specific needs, six confounding clinical factors including TNM stage, smoking history, gender, lymph, histological type, and race, were set as optional filter factors in the prognostic analysis. As showed in Figure 3A, each factor has 2–5 options for users to choose from.

 Validation of Previously Published BC Biomarkers

To test the reliability of prognosis prediction in our web server, we evaluated 21 prognostic biomarkers from 16 previously reported literatures in the OSblca web server, including KPNA2, TP53, and MYC (17–32). As shown in Table 2, 17 out of 21 (82%) previous reported prognostic biomarkers were showed to have significant prognostic potency in OSblca, while the remaining four previously reported prognostic biomarkers did not reach significance in OSblca. Among the 17 validated prognostic biomarkers, 11 genes showed significant prognostic abilities in the combined cohort.

The validation of previous reported prognostic biomarkers in OSblca.

Gene symbol Detection level Case Independent validation In reference In OSblca
P-value HR References P-value HR Cut off
KPNA2 Protein 611 Yes 0.030 1.38 (17) 0.001a 1.42 Upper 25%
HYAL1 Protein 220 Yes 0.019 1.76 (18) 0.021a 1.29 Upper 25%
TP53 Protein 152 No < 0.001 – (19) 0.037a 0.77 Upper 25%
MYC Protein 132 No 0.020 – (20) 0.050a 1.25 Upper 25%
RPS6 Protein 132 No < 0.010 – (20) 0.007a 0.71 Upper 25%
JMJD2A Protein 129 No 0.033 – (21) 0.026a 0.63 Upper 25%
MKi67 Protein 115 No < 0.050 – (22) 0.021a 1.29 Upper 25%
RRM1 Protein 84 No 0.001 – (23) 0.000a 1.68 Lower 25%
MMP2 mRNA 41 No < 0.05 – (25) 0.039a 1.26 Upper 25%
CDH2 mRNA 181 No < 0.001 – (26) 0.038a 1.26 Upper 25%
PTGS2 Protein 273 No 0.027 0.65 (24) 0.050b 0.72 Upper 25%
CDH3 mRNA 181 No < 0.010 – (26) 0.041c 2.30 Upper 25%
MDM2 Protein 84 No < 0.050 (27) 0.045d 1.89 Upper 25%
CCND3 Protein 157 No < 0.030 – (28) 0.039c 2.32 Upper 25%
CCND2 Protein 57 No 0.042 – (28) 0.047f 1.67 Lower 25%
LGALS3 mRNA 165 Yes < 0.001 – (29) 0.016e 0.61 Lower 25%
USP28 Protein 206 Yes < 0.001 – (30) 0.048c 0.29 Lower 30%
0.014d 0.38 Lower 30%
DIABLO Protein 84 No < 0.050 – (31) 0.239g 0.87 NA
RB1 Protein 311 No 0.030 – (25) 0.898g 1.02 NA
FGFR3 mRNA 114 No 0.035 – (32) 0.462g 0.92 NA
CCND1 Protein 157 No < 0.020 – (28) 0.997g 0.98 NA

Significant P-value validated in a combined cohort (OS);

Significant P-value validated in a combined cohort (DSS);

Significant P-value validated in dataset GSE32548, GSE48075, TCGA, and GSE13507, respectively;

No significance P-value validated in any cohorts, “–” means no HR data, “NA” means not applicable.

 Discussion

The discovery of prognostic biomarkers is a hot topic in translational research. In the current study, we present a convenient web server to assist researchers and clinicians to quickly screen and evaluate the prognostic value of genes in different cohorts of BC. As shown in a straightforward web interface, people without much bioinformatics experience can easily navigate OSblca to investigate genes of interests. In addition, users can perform survival analysis filtered by one or several factors according to the specific research purposes of their needs.

The validation of previously reported prognostic biomarkers in OSblac showed that our web tool is reliable and can be used in prognostic analysis for BC patients. Notably, 11 genes, such as KPNA2 and TP53, were confirmed as prognostic biomarkers in the combined cohort, which indicated that these genes may be more widely applied as prognostic candidates for BC patients.

In summary, OSblca is a free online survival analysis web server that allows clinicians and researchers to rapidly analyze the prognostic value of a given gene in BC. We will keep updating OSblca to make it more powerful for the users.

 Data Availability

Publicly available datasets were analyzed in this study. This data can be found here: http://bioinfo.henu.edu.cn/BLCA/BLCAList.jsp.

 Author Contributions

GZ, QW, MY, and XG collected data, developed the server, and drafted the paper. QY, YD, XS, YA, and HD set up the server and performed the analyses. LX, WZ, and YW contributed to data analysis and paper writing. All authors edited and approved the final manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

 References Bray F Ferlay J Soerjomataram I Siegel RL Torre LA Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. (2018) 68:394–424. 10.3322/caac.2149230207593 Knowles MA Hurst CD. Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer. (2015) 15:25–41. 10.1038/nrc381725533674 Grayson M. Bladder cancer. Nature. (2017) 551:S33. 10.1038/551S33a29117156 Babjuk M Bohle A Burger M Capoun O Cohen D Comperat EM . EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol. (2017) 71:447–61. 10.1016/j.eururo.2016.05.041 Netto GJ. Molecular biomarkers in urothelial carcinoma of the bladder: are we there yet? Nat Rev Urol. (2011) 9:41–51. 10.1038/nrurol.2011.19322158597 Sapre N Herle P Anderson PD Corcoran NM Hovens CM. Molecular biomarkers for predicting outcomes in urothelial carcinoma of the bladder. Pathology. (2014) 46:274–82. 10.1097/PAT.000000000000011024798156 Xylinas E Kluth LA Lotan Y Daneshmand S Rieken M Karakiewicz PI . Blood- and tissue-based biomarkers for prediction of outcomes in urothelial carcinoma of the bladder. Urol Oncol. (2014) 32:230–42. 10.1016/j.urolonc.2013.06.00924332648 Xie L Dang Y Guo J Sun X Xie T Zhang L . High KRT8 expression independently predicts poor prognosis for lung adenocarcinoma patients. Genes. (2019) 10:E36. 10.3390/genes1001003630634629 Bolenz C Lotan Y. Molecular biomarkers for urothelial carcinoma of the bladder: challenges in clinical use. Nat Clin Pract Urol. (2008) 5:676–85. 10.1038/ncpuro125919050710 van Rhijn BW van der Poel HG van der Kwast TH. Urine markers for bladder cancer surveillance: a systematic review. Eur Urol. (2005) 47:736–48. 10.1016/j.eururo.2005.03.01415925067 Guo X Tang Y Zhu W. Distinct esophageal adenocarcinoma molecular subtype has subtype-specific gene expression and mutation patterns. BMC Genomics. (2018) 19:769. 10.1186/s12864-018-5165-030355311 Choi W Ochoa A McConkey DJ Aine M Hoglund M Kim WY . Genetic alterations in the molecular subtypes of bladder cancer: illustration in the cancer genome atlas dataset. Eur Urol. (2017) 72:354–65. 10.1016/j.eururo.2017.03.01028365159 Liu J Lichtenberg T Hoadley KA Poisson LM Lazar AJ Cherniack AD . An integrated TCGA pan-cancer clinical data resource to drive high-quality survival outcome analytics. Cell. (2018) 173:400–16e11. 10.1016/j.cell.2018.02.052 29625055 Proctor I Stoeber K Williams GH. Biomarkers in bladder cancer. Histopathology. (2010) 57:1–13. 10.1111/j.1365-2559.2010.03592.x20579130 Samanic C Kogevinas M Dosemeci M Malats N Real FX Garcia-Closas M . Smoking and bladder cancer in Spain: effects of tobacco type, timing, environmental tobacco smoke, and gender. Cancer Epidemiol Biomarkers Prev. (2006) 15:1348–54. 10.1158/1055-9965.EPI-06-002116835335 Lotan Y Gupta A Shariat SF Palapattu GS Vazina A Karakiewicz PI . Lymphovascular invasion is independently associated with overall survival, cause-specific survival, and local and distant recurrence in patients with negative lymph nodes at radical cystectomy. J Clin Oncol. (2005) 23:6533–9. 10.1200/JCO.2005.05.51616116151 Jensen JB Munksgaard PP Sorensen CM Fristrup N Birkenkamp-Demtroder K Ulhoi BP . High expression of karyopherin-alpha2 defines poor prognosis in non-muscle-invasive bladder cancer and in patients with invasive bladder cancer undergoing radical cystectomy. Eur Urol. (2011) 59:841–8. 10.1016/j.eururo.2011.01.04821330047 Kramer MW Escudero DO Lokeshwar SD Golshani R Ekwenna OO Acosta K . Association of hyaluronic acid family members (HAS1, HAS2, and HYAL-1) with bladder cancer diagnosis and prognosis. Cancer. (2011) 117:1197–209. 10.1002/cncr.2556520960509 Youssef RF Shariat SF Kapur P Kabbani W Ghoneim T King E . Expression of cell cycle-related molecular markers in patients treated with radical cystectomy for squamous cell carcinoma of the bladder. Human Pathol. (2011) 42:347–55. 10.1016/j.humpath.2010.07.01221111452 Schultz L Albadine R Hicks J Jadallah S DeMarzo AM Chen YB . Expression status and prognostic significance of mammalian target of rapamycin pathway members in urothelial carcinoma of urinary bladder after cystectomy. Cancer. (2010) 116:5517–26. 10.1002/cncr.2550220939013 Kauffman EC Robinson BD Downes MJ Powell LG Lee MM Scherr DS . Role of androgen receptor and associated lysine-demethylase coregulators, LSD1 and JMJD2A, in localized and advanced human bladder cancer. Mol Carcinog. (2011) 50:931–44. 10.1002/mc.2075821400613 Wu P Liu S Zhang W Zhang Y Zhu G Wei D . Low-level Ki-67 expression as an independent predictor of bladder tumour recurrence in patients with primary upper tract urothelial carcinoma after radical nephroureterectomy. Jpn J Clin Oncol. (2015) 45:1175–81. 10.1093/jjco/hyv13926450700 Harshman LC Bepler G Zheng Z Higgins JP Allen GI Srinivas S. Ribonucleotide reductase subunit M1 expression in resectable, muscle-invasive urothelial cancer correlates with survival in younger patients. BJU Int. (2010) 106:1805–11. 10.1111/j.1464-410X.2010.09327.x20438561 Aziz A Lessard A Moore K Hovington H Latulippe E Larue H . Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2. BJU Int. (2011) 108:531–7. 10.1111/j.1464-410X.2010.09909.x21166751 Chan OTM Furuya H Pagano I Shimizu Y Hokutan K Dyrskjot L . Association of MMP-2, RB and PAI-1 with decreased recurrence-free survival and overall survival in bladder cancer patients. Oncotarget. (2017) 8:99707–21. 10.18632/oncotarget.2068629245935 Jager T Becker M Eisenhardt A Tilki D Totsch M Schmid KW . The prognostic value of cadherin switch in bladder cancer. Oncol Rep. (2010) 23:1125–32. 10.3892/or_0000074120204300 Shiina H Igawa M Shigeno K Yamasaki Y Urakami S Yoneda T . Clinical significance of mdm2 and p53 expression in bladder cancer. A comparison with cell proliferation and apoptosis. Oncology. (1999) 56:239–47. 10.1159/00001197110202280 Levidou G Saetta AA Karlou M Thymara I Pratsinis H Pavlopoulos P . D-type cyclins in superficial and muscle-invasive bladder urothelial carcinoma: correlation with clinicopathological data and prognostic significance. J Cancer Res Clin Oncol. (2010) 136:1563–71. 10.1007/s00432-010-0814-y20174823 Canesin G Gonzalez-Peramato P Palou J Urrutia M Cordon-Cardo C Sanchez-Carbayo M. Galectin-3 expression is associated with bladder cancer progression and clinical outcome. Tumour Biol. (2010) 31:277–85. 10.1007/s13277-010-0033-920401558 Guo G Xu Y Gong M Cao Y An R. USP28 is a potential prognostic marker for bladder cancer. Tumour Biol. (2014) 35:4017–22. 10.1007/s13277-013-1525-124347490 Mizutani Y Katsuoka Y Bonavida B. Prognostic significance of second mitochondria-derived activator of caspase (Smac/DIABLO) expression in bladder cancer and target for therapy. Int J Oncol. (2010) 37:503–8. 10.3892/ijo_0000069920596678 Sung JY Sun JM Chang Jeong B Il Seo S Soo Jeon S Moo Lee H . FGFR3 overexpression is prognostic of adverse outcome for muscle-invasive bladder carcinoma treated with adjuvant chemotherapy. Urol Oncol. (2014) 32:49 e23–31. 10.1016/j.urolonc.2013.07.01524360661

Funding. This work was supported by the National Natural Science Foundation of China (No.81602362), the program for Science and Technology Development in Henan Province (No.162102310391), the supporting grants of Henan University (No.2015YBZR048; No.B2015151), the program for Innovative Talents of Science and Technology in Henan Province (No.18HASTIT048), and Yellow River Scholar Program (No.H2016012), Kaifeng Science and Technology Major Project (No.18ZD008).